Chemical Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Immunogenic
cell
death
(ICD)
has
attracted
enormous
attention
over
the
past
decade
due
to
its
unique
characteristics
in
cancer
and
role
activating
innate
adaptive
immune
responses
against
tumours.
Many
efforts
have
been
dedicated
screening,
identifying
discovering
ICD
inducers,
resulting
validation
of
several
based
on
metal
complexes.
In
this
review,
we
provide
a
comprehensive
summary
current
metal-based
their
molecular
mechanisms
for
triggering
initiation
subsequent
protective
antitumour
responses,
along
with
considerations
validating
both
vitro
vivo.
We
also
aim
offer
insights
into
future
development
complexes
enhanced
ICD-inducing
properties
applications
potentiating
immunity.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(21)
Published: Feb. 16, 2024
Immunotherapy
represents
a
revolutionary
paradigm
in
cancer
management,
showcasing
its
potential
to
impede
tumor
metastasis
and
recurrence.
Nonetheless,
challenges
including
limited
therapeutic
efficacy
severe
immune-related
side
effects
are
frequently
encountered,
especially
solid
tumors.
Hydrogels,
class
of
versatile
materials
featuring
well-hydrated
structures
widely
used
biomedicine,
offer
promising
platform
for
encapsulating
releasing
small
molecule
drugs,
biomacromolecules,
cells
controlled
manner.
Immunomodulatory
hydrogels
present
unique
capability
augmenting
immune
activation
mitigating
systemic
toxicity
through
encapsulation
multiple
components
localized
administration.
Notably,
based
on
biopolymers
have
gained
significant
interest
owing
their
biocompatibility,
environmental
friendliness,
ease
production.
This
review
delves
into
the
recent
advances
bio-based
immunotherapy
synergistic
combinatorial
approaches,
highlighting
diverse
applications.
It
is
anticipated
that
this
will
guide
rational
design
field
immunotherapy,
fostering
clinical
translation
ultimately
benefiting
patients.
Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
14(6), P. 2475 - 2504
Published: March 20, 2024
Resistance
to
cancer
immunotherapy
is
mainly
attributed
poor
tumor
immunogenicity
as
well
the
immunosuppressive
microenvironment
(TME)
leading
failure
of
immune
response.
Numerous
therapeutic
strategies
including
chemotherapy,
radiotherapy,
photodynamic,
photothermal,
magnetic,
chemodynamic,
sonodynamic
and
oncolytic
therapy,
have
been
developed
induce
immunogenic
cell
death
(ICD)
cells
thereby
elicit
boost
antitumor
However,
many
challenges
hamper
clinical
application
ICD
inducers
resulting
in
modest
Here,
we
outline
current
state
using
nanomedicines
for
boosting
cells.
Moreover,
synergistic
approaches
used
combination
with
inducing
remodeling
TME
Frontiers in Cell and Developmental Biology,
Journal Year:
2024,
Volume and Issue:
12
Published: May 7, 2024
Immunotherapy
has
emerged
as
a
promising
cancer
treatment
option
in
recent
years.
In
immune
“hot”
tumors,
characterized
by
abundant
cell
infiltration,
immunotherapy
can
improve
patients’
prognosis
activating
the
function
of
cells.
By
contrast,
“cold”
tumors
are
often
less
sensitive
to
owing
low
immunogenicity
tumor
cells,
an
inhibitory
microenvironment,
and
series
immune-escape
mechanisms.
Immunogenic
death
(ICD)
is
cellular
process
facilitate
transformation
eliciting
innate
adaptive
responses
through
release
(or
exposure
to)
damage-related
molecular
patterns.
Accumulating
evidence
suggests
that
various
traditional
therapies
induce
ICD,
including
chemotherapy,
targeted
therapy,
radiotherapy,
photodynamic
therapy.
this
review,
we
summarize
biological
mechanisms
hallmarks
ICD
introduce
some
newly
discovered
technologically
innovative
inducers
activate
system
at
level.
Furthermore,
also
discuss
clinical
applications
combing
with
immunotherapy.
This
review
will
provide
valuable
insights
into
future
development
ICD-related
combination
therapeutics
potential
management
for
tumors.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
36(9)
Published: Dec. 8, 2023
Immunotherapy
using
an
immune-checkpoint
blockade
has
significantly
improved
its
therapeutic
effects.
CM-272,
which
is
a
novel
epigenetic
inhibitor
of
G9a,
induces
immunogenic
cell
death
(ICD)
for
recovering
the
sensitivity
to
anti-PD-1
antibodies;
however,
efficacy
CM-272
greatly
limited
by
promoting
transcription
activity
HIF-1α
form
hypoxic
environment.
Here,
Fe
World Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
30(13), P. 1815 - 1835
Published: April 2, 2024
Colorectal
cancer
(CRC)
is
a
complex
disease
with
diverse
etiologies
and
clinical
outcomes.
Despite
considerable
progress
in
development
of
CRC
therapeutics,
challenges
remain
regarding
the
diagnosis
management
advanced
stage
metastatic
(mCRC).
In
particular,
five-year
survival
rate
very
low
since
mCRC
currently
rarely
curable.
Over
past
decade,
treatment
has
significantly
improved
introduction
immunotherapies,
specifically
immune
checkpoint
inhibitors.
Therapies
aimed
at
blocking
checkpoints
such
as
PD-1,
PD-L1,
CTLA-4
target
inhibitory
pathways
system,
thereby
enhance
anti-tumor
immunity.
These
therapies
thus
have
shown
promising
results
many
trials
alone
or
combination.
The
efficacy
safety
immunotherapy,
either
combination
CRC,
been
investigated
several
trials.
Clinical
trials,
including
KEYNOTE-164
CheckMate
142,
led
to
Food
Drug
Administration
approval
PD-1
inhibitors
pembrolizumab
nivolumab,
respectively,
for
patients
unresectable
microsatellite
instability-high
deficient
mismatch
repair
CRC.
Unfortunately,
these
drugs
benefit
only
small
percentage
patients,
benefits
immunotherapy
remaining
elusive
vast
majority
patients.
To
this
end,
primary
secondary
resistance
remains
significant
issue,
further
research
necessary
optimize
use
identify
biomarkers
predict
response.
This
review
provides
comprehensive
overview
involving
underlying
rationale,
faced,
potential
future
steps
improve
prognosis
likelihood
successful
field
are
discussed.
